Natriuretic Peptides as Diagnostics: How a Hormone Became a Blood Test

July 3, 2026 13 min read The Human Machine

natriuretic-peptidesBNPheart-failurecardiac-biomarkersbiochemistrydiagnostics

Contents

A stretched heart muscle cell does something most cells never do: it secretes a hormone whose entire job is to tell the kidneys and blood vessels to relieve the pressure the heart is under. That hormone, B-type natriuretic peptide, and the inactive fragment produced alongside it, NT-proBNP, have become two of the most frequently ordered blood tests in cardiology and emergency medicine — not because anyone designed them as diagnostic markers, but because the same cleavage event that activates the hormone happens to dump a second, stable, easily measured molecule into the bloodstream in a fixed, predictable ratio. Understanding why the test works the way it does — and where it quietly doesn’t — starts with understanding the actual physiological system the heart is running, not just the reference range printed on a lab report.

The Natriuretic Peptide System: A Hormonal Pressure-Relief Valve

The natriuretic peptide system was identified in 1981, when researcher Adolfo de Bold and colleagues found that injecting rats with an extract of atrial heart tissue triggered rapid, dramatic natriuresis and diuresis — salt and water excretion — establishing for the first time that the heart itself, not just the kidney and adrenal glands, directly regulates blood volume and pressure through its own hormone. That first molecule, atrial natriuretic peptide (ANP), was followed by the discovery of B-type natriuretic peptide (BNP, originally isolated from porcine brain tissue, which is where the “B” naming stuck despite its primary source turning out to be the heart) and C-type natriuretic peptide (CNP), each produced by different tissues and each binding a different member of a three-receptor family: NPR-A (preferring ANP and BNP), NPR-B (preferring CNP), and NPR-C, a clearance receptor that binds all three and removes them from circulation rather than transmitting a signal.

Unlike the GPCR/cAMP signaling logic covered for most peptide hormones in /posts/peptide-hormones-vs-steroid-hormones/, natriuretic peptide receptors are themselves guanylyl cyclases — the receptor and the signal-generating enzyme are the same transmembrane protein, and ligand binding directly triggers the intracellular production of cyclic GMP rather than cyclic AMP, a parallel but mechanistically distinct second-messenger system.

The physiological loop BNP participates in is a straightforward negative-feedback controller aimed at a single problem: excessive volume or pressure load on the heart.

Ventricular wall stretch (volume/pressure overload)
        |
        v
Cardiac myocytes increase proBNP synthesis and secretion
        |
        v
proBNP cleaved --> BNP (active) + NT-proBNP (inactive fragment)
        |
        v
BNP binds NPR-A on kidney, vasculature, adrenal targets
        |
        +---> Kidney: increased sodium and water excretion (natriuresis/diuresis)
        |
        +---> Blood vessels: vasodilation, reduced systemic vascular resistance
        |
        +---> Adrenal cortex: suppressed aldosterone release
        |
        v
Reduced blood volume and vascular resistance
        |
        v
Reduced ventricular wall stretch  ---> feedback loop closes

The system exists because a heart under chronic volume or pressure overload — from hypertension, valve disease, or a weakening pump — is exactly the situation where reducing venous return and vascular resistance provides real, if partial, relief, and the heart is uniquely positioned to sense that overload directly, at the source, faster than any distant kidney-based sensor could.

Not Every Natriuretic Peptide Is a Heart-Failure Test

The clinical spotlight on BNP and NT-proBNP can obscure that the natriuretic peptide family has members doing genuinely different jobs, which is worth separating out precisely because it explains why only two of these molecules ever became routine diagnostics. ANP, the founding member de Bold identified in 1981, is stored pre-made in atrial granules and released rapidly in response to atrial stretch, giving it a much faster on-off response than BNP’s synthesize-on-demand ventricular secretion — a real kinetic difference, but ANP never achieved BNP’s diagnostic prominence largely because its very short half-life and technically difficult assay made it a poor fit for routine clinical lab work compared to the more stable NT-proBNP fragment. CNP, in contrast, isn’t primarily a cardiac hormone at all — it’s produced largely by vascular endothelial cells and acts locally, in a paracrine rather than endocrine fashion, on NPR-B receptors to regulate vascular tone and bone growth, and it circulates at levels too low and too locally confined to serve as a systemic heart-failure marker. A fifth family member, urodilatin, is produced directly by kidney tubule cells from the same proANP precursor gene and acts locally within the kidney to promote sodium excretion, never entering the systemic circulation in meaningful amounts at all.

The practical reason BNP and NT-proBNP, specifically, became the clinical standard rather than ANP or CNP is a combination of assay stability, ventricular (rather than atrial or purely local vascular) origin tracking more directly with the chronic pressure-and-volume overload that defines heart failure, and — again — the accident of furin cleavage producing a long-lived, easily standardized fragment alongside the active hormone. It’s a reminder that “the heart makes a hormone that becomes a useful blood test” undersells how much of a diagnostic’s real-world adoption depends on assay engineering as much as on the underlying biology being clinically relevant.

From proBNP to Two Blood Tests: The Cleavage That Created a Biomarker

The reason a heart-failure blood test exists at all is a manufacturing detail. Cardiac myocytes don’t secrete BNP directly — they secrete the 108-amino-acid prohormone proBNP, which is glycosylated at several sites in the Golgi apparatus and then cleaved, primarily by the enzyme furin, into two fragments released into the bloodstream together in a fixed, roughly 1:1 stoichiometric ratio: the 32-amino-acid active hormone BNP, and the 76-amino-acid inactive N-terminal fragment, NT-proBNP. Because both fragments are produced from the same precursor in a fixed ratio, either one is, in principle, a proxy for how much proBNP the stressed heart is making — but the two fragments behave differently enough in the bloodstream that clinical labs routinely offer both as separate, non-interchangeable tests.

Property	BNP	NT-proBNP
Length	32 amino acids	76 amino acids
Biological activity	Active hormone, binds NPR-A	Inactive fragment, no known receptor signaling role
Clearance mechanism	NPR-C receptor-mediated clearance plus enzymatic degradation by neprilysin	Renal clearance only, no receptor-mediated removal
Plasma half-life	Short (roughly 20 minutes)	Longer, more stable
Effect of renal impairment on levels	Elevated	More strongly elevated (renal clearance is its only removal route)
Effect of neprilysin-inhibitor drugs	Falsely elevated (see below)	Unaffected

NT-proBNP’s longer half-life and its immunity to enzymatic degradation make it a more stable, more reproducible assay target in practice, which is a large part of why it has become the more commonly ordered of the two tests in many health systems today, even though BNP was the first to reach widespread clinical use.

Reading the Number: Cutoffs and What They Mean

Neither test works with a single universal cutoff — natriuretic peptide levels rise with age even in people without heart failure, largely reflecting the gradual decline in renal clearance and cumulative subclinical cardiac stress that comes with aging, so modern diagnostic thresholds are age-stratified rather than flat.

Age group	NT-proBNP rule-in threshold (acute dyspnea, ESC/PRIDE-derived)
Under 50 years	≥450 pg/mL
50–74 years	≥900 pg/mL
75 years and older	≥1800 pg/mL

For BNP specifically, a commonly used interpretive scheme treats values under roughly 100 pg/mL as evidence against acute heart failure, values above roughly 400 pg/mL as strongly suggestive of it, and the intermediate range as genuinely indeterminate, requiring additional clinical correlation rather than a binary readout. The existence of that indeterminate band is itself an honest acknowledgment that a single stretch-triggered hormone level is a probabilistic signal layered on top of a specific patient’s age, renal function, and body habitus — not a binary switch.

A simplified version of the logic an emergency department decision pathway follows looks like this:

function evaluate_dyspnea(nt_probnp_pg_ml, age_years):
    if age_years < 50:
        rule_in_threshold = 450
    elif age_years < 75:
        rule_in_threshold = 900
    else:
        rule_in_threshold = 1800

    if nt_probnp_pg_ml < 300:
        return "Heart failure unlikely, consider alternative diagnosis"
    elif nt_probnp_pg_ml >= rule_in_threshold:
        return "Heart failure likely, proceed with HF workup and treatment"
    else:
        return "Indeterminate: correlate with echocardiogram and clinical exam"

This is a real simplification of the logic embedded in emergency-medicine dyspnea protocols derived from trials like PRIDE and ICON — a single low cutoff below which heart failure is effectively ruled out, an age-adjusted high cutoff above which it’s ruled in, and a deliberately wide gray zone in between that exists precisely because the test’s confounders (covered next) are common enough that no single number can be trusted blindly.

The Confounders: Why the Number Lies Sometimes

The single biggest practical limitation of natriuretic peptide testing is that BNP and NT-proBNP levels are influenced by several conditions that have nothing to do with acute heart failure, in both directions.

Obesity substantially lowers natriuretic peptide levels for reasons that are still only partly understood — proposed mechanisms include enhanced peptide clearance associated with obesity-related renal hyperfiltration, and possibly increased expression of the NPR-C clearance receptor in adipose tissue itself. The clinical consequence is measurable and significant: using standard cutoffs, one substudy of the PRIDE trial found BNP testing falsely negative in roughly 20% of confirmed heart-failure cases in both overweight and obese patients, and NT-proBNP falsely negative in up to 15% of obese patients — a real, clinically important blind spot in exactly the population where obesity-related cardiac strain is already a growing diagnostic concern.

In the other direction, renal insufficiency, advanced age, atrial fibrillation, and systemic inflammation all tend to elevate both BNP and NT-proBNP independent of any acute cardiac decompensation, which is the main driver of false positives — one analysis found roughly half of patients presenting with an elevated NT-proBNP had no heart failure on further workup, with the elevation instead attributable to renal dysfunction, atrial fibrillation, or another non-cardiac driver.

Confounder	Effect on natriuretic peptide levels
Obesity	Decreased (false negative risk)
Renal insufficiency	Increased (false positive risk)
Advanced age	Increased (raises the correct diagnostic threshold, doesn’t invalidate the test)
Atrial fibrillation	Increased
Neprilysin-inhibitor drug therapy	BNP falsely increased; NT-proBNP unaffected

That last row is one of the more counterintuitive interactions in modern cardiology practice, and it’s a direct consequence of the biochemistry covered above.

Turning the Hormone Itself Into a Drug

If a stretched heart already secretes a hormone whose job is to relieve pressure and volume overload, one obvious therapeutic idea is to make more of that hormone’s effect available rather than trying to block a separate pathway — and that’s exactly the mechanism behind sacubitril/valsartan (Entresto), an angiotensin receptor–neprilysin inhibitor (ARNI) approved for heart failure with reduced ejection fraction. Neprilysin is one of the enzymes responsible for degrading circulating BNP; sacubitril inhibits neprilysin, which slows BNP’s breakdown and effectively amplifies the natriuretic, diuretic, and vasodilatory signal the failing heart is already trying to send, while valsartan simultaneously blocks the angiotensin II pathway working in the opposite physiological direction. In the pivotal PARADIGM-HF trial of over 8,400 patients, sacubitril/valsartan reduced the combined endpoint of cardiovascular death or heart failure hospitalization by 20% compared with the older ACE-inhibitor standard of care, enalapril — a substantial effect size that helped make ARNI therapy a guideline-recommended first-line option.

Here’s the diagnostic wrinkle this creates: because sacubitril works specifically by inhibiting neprilysin-mediated BNP degradation, a patient on sacubitril/valsartan will show artificially elevated BNP levels that reflect reduced clearance rather than worsening heart failure, making the BNP test unreliable for monitoring disease status in exactly the population most likely to be tested regularly. NT-proBNP, which is cleared entirely by the kidney and isn’t a neprilysin substrate at all, is unaffected by the drug and remains the correct test to order for any patient on ARNI therapy — a case where understanding the specific enzymatic mechanism behind a biomarker isn’t academic trivia, it’s the difference between correctly and incorrectly interpreting a lab result that directly drives treatment decisions.

Honest Trade-offs

A single natriuretic peptide number is a probabilistic signal, not a diagnosis. The wide indeterminate zone built into every major interpretive algorithm exists because the confounders above are common enough in real patient populations that a number alone, without clinical correlation and imaging, is genuinely insufficient in a meaningful fraction of cases.
The obesity-driven false-negative rate is a real equity concern, not a footnote. A test that under-detects heart failure specifically in obese patients, in a population where obesity-related cardiac strain is already common and rising, is a meaningful diagnostic gap that current single-threshold or even age-adjusted-only protocols don’t fully solve.
NT-proBNP’s greater stability is an assay convenience, not proof it’s the “better” biomarker in every clinical question. BNP’s biological activity and shorter half-life make it more responsive to acute, rapid changes in cardiac status in some contexts, even though its instability makes it a less convenient lab test to standardize.
A drug that improves outcomes by amplifying a biomarker’s own hormone breaks that biomarker for monitoring — this is a real, ongoing clinical management problem, not a rare edge case. ARNI therapy is now common enough in heart-failure management that NT-proBNP-only monitoring protocols for patients on sacubitril/valsartan are a standard, necessary workaround rather than a niche caveat.
The natriuretic peptide system’s therapeutic ceiling is limited by the same physiology that makes it a good biomarker. Because BNP’s natural effect is real but modest relative to the severity of decompensated heart failure, amplifying it via neprilysin inhibition provides a meaningful but incremental benefit on top of, not a replacement for, standard heart-failure therapy targeting other pathways.

Verdict

The natriuretic peptide system is a genuine example of the heart acting as an endocrine organ in its own defense — sensing its own mechanical overload and secreting a hormone aimed directly at relieving it, a feedback loop identified only in 1981 and now central to both diagnosing and treating heart failure. That BNP and NT-proBNP became two of medicine’s most useful cardiac biomarkers is almost an accident of biochemistry: the same furin cleavage event that activates the hormone happens to release a second, stable, easily measured fragment in a fixed ratio, and decades of clinical trial data have since mapped out exactly how to read that number, exactly which patients it misleads, and exactly which drug quietly breaks half of it. Understanding a biomarker this well — including its blind spots in obese patients and its specific unreliability on ARNI therapy — is what separates a diagnostic test used correctly from one used as an unquestioned number on a lab report, and the natriuretic peptide system is as good a case study as exists in modern medicine for why that distinction matters.